May 24, 2016 | Israeli cancer detection company Nucleix has raised $3 million from Morris Kahn’s Aurum Ventures MKI, OrbiMed Israel Partners, and Zohar Zisapel, OrbiMed and Zohar Zisapel invested in the startup’s first $5.5 million financing round and the company has also raised $3 million from private investors. Nucleix is involved in the relatively new research field of epigenetics (a situation in which identical genes express themselves in different ways) in order to detect different types of cancers. The company’s first test for the detection of bladder cancer could be available in Europe within a couple of months. Nucleix was founded in 2008 by CEO Elon Ganor a former CEO of voice-over-IP pioneer VocalTec, and Weizmann Institute graduates VR research Dr. Danny Frumkin, and VP development Dr. Danny Wasserstrom. Dr Opher Shapira is president and COO.